- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Zetia is a cholesterol absorption inhibitor primarily used as an adjuvant therapy for primary hypercholesterolemia. The standard dose is 10mg o...
The use of Zetia requires special attention to liver enzyme abnormalities, muscle symptoms, and drug interaction risks. During the treatment pe...
Common side effects of Zetia include diarrhea, joint pain, and fatigue, most of which are mild and self relieving. Effective management can be ...
The administration of ezetimibe (Zetia) requires attention to the timing of dosing, handling of missed doses, and the principles of discontinua...
Targeted management is necessary for joint pain, nausea, and photosensitive reactions that may occur during treatment with Encorafenib. Joint p...
Encorafenib is a targeted drug for BRAFV600E mutant melanoma, exerting anti-tumor effects by inhibiting BRAF kinase activity. The following pro...
Encorafenib is a BRAF inhibitor primarily used to treat melanoma, colorectal cancer, and non-small cell lung cancer with BRAFV600E or V600K mut...
The contraindication population for Conafenib mainly includes BRAF wild-type tumor patients and patients with severe liver function impairment,...
Tucatinib/tocatinib is an oral tyrosine kinase inhibitor targeting HER2 protein, which is particularly suitable for the treatment of HER2 posit...
The common side effects of Tucatinib include nausea, fatigue, and hand foot syndrome, which require targeted management to alleviate symptoms a...
